AKAP7 RNAi Summary
| Specificity |
Homo sapiens A kinase (PRKA) anchor protein 7 (AKAP7), transcript variant alpha, mRNA
|
| Gene |
AKAP7
|
Applications/Dilutions
| Application Notes |
This RNAi causes protein knockdown.
|
Packaging, Storage & Formulations
| Storage |
Store at -20C. Avoid freeze-thaw cycles.
|
Notes
This product is produced by and distributed for Abnova, a company based in Taiwan.
Alternate Names for AKAP7 RNAi
- A kinase (PRKA) anchor protein 7
- AKAP 18
- AKAP15
- AKAP18A-kinase anchor protein 7 isoform alpha
- AKAP-7 isoform gamma
- AKAP-7 isoforms alpha and beta
- A-kinase anchor protein 18 kDa
- A-kinase anchor protein 7 isoform gamma
- A-kinase anchor protein 7 isoforms alpha and beta
- A-kinase anchor protein 7
- A-kinase anchor protein 9 kDa
- A-kinase anchor protein, 18-kD
- A-kinase anchoring protein 18
- protein kinase A anchoring protein 7
- Protein kinase A-anchoring protein 7 isoform gamma
- Protein kinase A-anchoring protein 7 isoforms alpha/beta
Background
Position of the Chimera RNAi. The related RNAi products listed were designed from different accesion number but sharing the same RNAi sequence. Chimera RNA interference (chimera RNAi) is process by which small interfering RNA/DNA chimera triggers the destruction of mRNA for the original gene. The discovery work, design, and application of chimera RNAi has been pioneered by Professor Kaoru Saigo and Dr. Kumiko Ui-Tei at the University of Tokyo. Chimera RNAi has many advantages over the conventional siRNAs. First, it has been demonstrated to have reliable knock-down for over 10,000 human genes. Because the human genome is composed of an intricate, genetic network, chimera RNAis unique design has successfully obviated the off-target effects including microRNA-based influence. Another advantage of the chimera RNAi technology is its effectiveness at low concentrations (0.5nM to 5nM); only mRNA is destroyed so genomic genes are not affected. Finally, having both the sense and anti-sense strands consisting RNA/DNA chimera, it offers much greater compound stability for streamlining in vitro and in vivo assays and applications while minimizing interferon induction and other adverse reactions.
